{
    "body": "Can the iPS cell technology be used in Fanconi anemia therapy?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/20224565", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19483674"
    ], 
    "ideal_answer": [
        "iPS cell technology can be used for the generation of disease-corrected, patient-specific cells with potential value for cell therapy applications in Fanconi anemia."
    ], 
    "exact_answer": "yes", 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057026", 
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051856", 
        "http://www.disease-ontology.org/api/metadata/DOID:13636", 
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005199", 
        "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064987"
    ], 
    "type": "yesno", 
    "id": "54edef0594afd6150400000d", 
    "snippets": [
        {
            "offsetInBeginSection": 309, 
            "offsetInEndSection": 507, 
            "text": "We explain a protocol for the reproducible generation of genetically corrected iPSCs starting from the skin biopsies of Fanconi anemia patients using retroviral transduction with OCT4, SOX2 and KLF4", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20224565", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 509, 
            "offsetInEndSection": 645, 
            "text": "Before reprogramming, the fibroblasts and/or keratinocytes of the patients are genetically corrected with lentiviruses expressing FANCA.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/20224565", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 96, 
            "text": "Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19483674", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 322, 
            "offsetInEndSection": 610, 
            "text": "Here we show that, on correction of the genetic defect, somatic cells from Fanconi anaemia patients can be reprogrammed to pluripotency to generate patient-specific iPS cells. These cell lines appear indistinguishable from human embryonic stem cells and iPS cells from healthy individuals", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19483674", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 612, 
            "offsetInEndSection": 823, 
            "text": "Most importantly, we show that corrected Fanconi-anaemia-specific iPS cells can give rise to haematopoietic progenitors of the myeloid and erythroid lineages that are phenotypically normal, that is, disease-free", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19483674", 
            "endSection": "abstract"
        }
    ]
}